Alternatives to conventional antimicrobial drugs: A review of future prospects

Veterinary Dermatology

Volumn 23, Issue 4, 2012, Pages

  Lloyd, David H ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ANTIINFECTIVE AGENT; BACTERIAL VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BACTERIAL INFECTION; DRUG DEVELOPMENT;

ALPHA-DEFENSINS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; DRUG DISCOVERY;

BACTERIA (MICROORGANISMS); MAMMALIA; STAPHYLOCOCCUS;

EID: 84864149896     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2012.01042.x     Document Type: Article

References (62)

1. Gould IM. Antibiotic resistance: the perfect storm. Int J Antimicrob Agents 2009; 34(Suppl. 3): S2-S5.
2. Guardabassi L, Schwarz S, Lloyd DH. Pet animals as reservoirs of antimicrobial-resistant bacteria. J Antimicrob Chemother 2004; 54: 321-332.
3. Perreten V, Kadlec K, Schwarz S et al. Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: an international multicentre study. J Antimicrob Chemother 2010; 65: 1145-1154.
4. Health Protection Agency website. Surveillance of healthcare associated infections report: 2008. Available at: Accessed 6 December 2011.
5. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
6. D'Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 2011; 477: 457-461.
7. Hernández A, Sánchez MB, Martínez JL. Quinolone resistance: much more than predicted. Front Microbiol 2011; 2: e22.
8. Fleischmann R, Adams M, White O et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995; 269: 496-512.
9. Costa SS, Falcão C, Viveiros M et al. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol 2011; 11: 241.
10. Fernebro J. Fighting bacterial infections-future treatment options. Drug Resist Updat 2011; 14: 125-139.
11. Lee ER, Blount FK, Breaker RR. Metabolite-sensing riboswitches as antibacterial drug targets. In: Miller AA, Miller PF, eds. Emerging Trends in Antibacterial Discovery. Answering the Call to Arms. Norwich: Caister Academic Press, 2011; 107-130.
12. Blount KF, Breaker RR. Riboswitches as antibacterial drug targets. Nat Biotechnol 2006; 24: 1558-1564.
13. Sudarsan N, Cohen-Chalamish S, Nakamura S et al. Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. Chem Biol 2005; 12: 1325-1335.
14. Stahl DA, Lane DJ, Olsen GJ et al. Characterization of a Yellowstone hot spring microbial community by 5S rRNA sequences. Appl Environ Microbiol 1985; 49: 1379-1384.
15. Brady SF, Clardy J. Long-chain N-acyl amino acid antibiotics isolated from heterologously expressed environmental DNA. J Am Chem Soc 2000; 122: 12903-12904.
16. Wang GY, Graziani E, Waters B et al. Novel natural products from soil DNA libraries in a streptomycete host. Org Lett 2000; 2: 2401-2404.
17. Gillespie DE, Brady SF, Bettermann AD et al. Isolation of antibiotics turbomycin A and B from a metagenomic library of soil microbial DNA. Appl Environ Microbiol 2002; 68: 4301-4306.
18. Courtois S, Cappellano CM, Ball M et al. Recombinant environmental libraries provide access to microbial diversity for drug discovery from natural products. Appl Environ Microbiol 2003; 69: 49-55.
19. Allen HK, Moe LA, Rodbumrer J et al. Functional metagenomics reveals diverse β-lactamases in a remote Alaskan soil. ISME J 2009; 3: 243-251.
20. Handelsman J. Metagenomics: application of genomics to uncultured microorganisms. Microbiol Mol Biol Rev 2004; 68: 669-685.
21. Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 2007; 64: 922-933.
22. Pena OM, Hale JDF, Hancock RDW. Host defence peptides. In: Miller AA, Miller PF, eds. Emerging Trends in Antibacterial Discovery. Answering the Call to Arms. Norwich: Caister Academic Press, 2011: 323-344.
23. Sang Y, Blecha F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim Health Res Rev 2008; 9: 227-235.
24. Oren F. Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signalling pathways. Cell Microbiol 2005; 7: 1387-1397.
25. van Damme CM, Willemse T, van Dijk A et al. Altered cutaneous expression of β-defensins in dogs with atopic dermatitis. Mol Immunol 2009; 46: 2449-2455.
26. Fazakerley J, Crossley J, McEwan N et al. In vitro antimicrobial efficacy of β-defensin 3 against Staphylococcus pseudintermedius isolates from healthy and atopic canine skin. Vet Dermatol 2010; 21: 463-468.
27. Dobson A, Cotter PD, Ross RP et al. Bacteriocin production as a probiotic trait? Appl Environ Microbiol. 2012; 78: 1-6.
28. Abriouel H, Franz CM, Ben Omar N et al. Diversity and applications of Bacillus bacteriocins. FEMS Microbiol Rev 2011; 35: 201-232.
29. Perron GG, Zasloff M, Bell G. Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci 2006; 273: 251-256.
30. Baltzer SA, Brown MH. Antimicrobial peptides: promising alternatives to conventional antibiotics. J Mol Microbiol Biotechnol 2011; 20: 228-235.
31. Gill J, Young RF. Therapeutic applications of phage biology: history, practice and recommendations. In: Miller AA, Miller PF, eds. Emerging Trends in Antibacterial Discovery. Answering the Call to Arms. Norwich: Caister Academic Press, 2011: 367-410.
32. Górski A, Miedzybrodzki R, Borysowski J et al. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 2009; 10: 766-774.
33. Leszczyński P, Weber-Dabrowska B, Kohutnicka M et al. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker - case report. Folia Microbiol (Praha) 2006; 51: 236-238.
34. Johnson RP, Gyles CL, Huff WE et al. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Anim Health Res Rev 2008; 9: 201-215.
35. Hawkins C, Harper D, Burch D et al. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol 2010; 146: 309-313.
36. Gill JJ, Pacan JC, Carson ME et al. Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob Agents Chemother 2006; 50: 2912-2918.
37. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol 2006; 296: 5-14.
38. Donald RGK, Anderson AS. Current strategies for antibacterial vaccine development. In: Miller AA, Miller PF, eds. Emerging Trends in Antibacterial Discovery. Answering the Call to Arms. Norwich: Caister Academic Press, 2011: 283-302.
39. Clarke SR, Mohamed R, Bian L et al. The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin. Cell Host Microbe 2007; 1: 199-212.
40. Pereira UP, Oliveira DG, Mesquita LR et al. Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. Vet Microbiol 2011; 148: 117-124.
41. DeBoer DJ, Moriello KA, Thomas CB et al. Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent superficial pyoderma in dogs. Am J Vet Res 1990; 51: 636-639.
42. Curtis CF, Lamport AI, Lloyd DH. Masked, controlled study to investigate the efficacy of a Staphylococcus intermedius autogenous bacterin for the control of canine idiopathic recurrent superficial pyoderma. Vet Dermatol 2006; 17: 163-168.
43. Bannoehr J, Ben Zakour NL, Reglinski M et al. Genomic and surface proteomic analysis of the canine pathogen Staphylococcus pseudintermedius reveals proteins that mediate adherence to the extracellular matrix. Infect Immun 2011; 79: 3074-3086.
44. Weisman LE, Thackray HM, Steinhorn RH et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011; 128: 271-279.
45. Nelson AM, Young VB. The indigenous human microbiota. In: Miller AA, Miller PF, eds. Emerging Trends in Antibacterial Discovery. Answering the Call to Arms. Norwich: Caister Academic Press, 2011; 225-240.
46. Sekirov I, Finlay BB. Human and microbe: united we stand. Nat Med 2006; 12: 736-737.
47. Wu S, Piscitelli C, de Lencastre H et al. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb Drug Resist 1996; 2: 435-441.
48. Reid G, Younes JA, Van der Mei HC et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011; 9: 27-38.
49. Deshpande GC, Rao SC, Keil AD et al. Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med 2011; 9: 92.
50. Kim JY, Kwon JH, Ahn SH et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol 2010; 21: e386-e393.
51. Marsella R. Evaluation of Lactobacillus rhamnosus strain GG for the prevention of atopic dermatitis in dogs. Am J Vet Res 2009; 70: 735-740.
52. Gueniche A, Knaudt B, Schuck E et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008; 159: 1357-1363.
53. Saijonmaa-Koulumies L, Lloyd DH. Colonization of neonatal puppies by Staphylococcus intermedius. Vet Dermatol 2002; 13: 123-130.
54. Saijonmaa-Koulumies L, Myllys V, Lloyd DH. Diversity and stability of the Staphylococcus intermedius flora in three bitches and their puppies. Epidemiol Infect 2003; 131: 931-937.
55. Muñoz P, Hortal J, Giannella M et al. Nasal carriage of S. aureus increases the risk of surgical site infection after major heart surgery. J Hosp Infect 2008; 68: 25-31.
56. Light IJ, Walton RL, Sutherland JM et al. Use of bacterial interference to control a staphylococcal nursery outbreak. Deliberate colonization of all infants with the 502A strain of Staphylococcus aureus. Am J Dis Child 1967; 113: 291-300.
57. Nicoll TR, Jensen MM. Staphylococcosis of turkeys. 5 Large-scale control programs using bacterial interference. Avian Dis 1987; 31: 85-88.
58. Allaker RP, Lloyd DH, Smith IM. Prevention of exudative epidermitis in gnotobiotic piglets by bacterial interference. Vet Rec 1988; 123: 597-598.
59. Antunes LC, Ferreira RB, Buckner MM et al. Quorum sensing in bacterial virulence. Microbiology 2010; 156: 2271-2282.
60. Sung JML, Chantler PD, Lloyd DH. The accessory gene regulator locus of Staphylococcus intermedius. Infect Immun 2006; 74: 2947-2956.
61. Loeffler A, Baines S, Toleman M et al. In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets. J Antimicrob Chemother 2008; 62: 1301-1304.
62. Loeffler A, Linek M, Moodley A et al. First report of multi-resistant, mecA-positive Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Vet Dermatol 2007: 18; 412-421.